NEW YORK (GenomeWeb) – Foundation Medicine has inked a collaboration with Merck to develop companion diagnostic tests for use with Merck's anti-PD-1 immunotherapy drug Keytruda (pembrolizumab).

Under the agreement announced today, the companies plan to develop a pan-cancer CDx to measure microsatellite instability (MSI), CDx tests for tumor mutational burden (TMB), and other novel biomarkers of response.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
26
Sponsored by
Lexogen

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul
10
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.